The HDACis were used to boost HERV expression in ovarian cancer cells (“shock”), and the TLR7/8 agonists provided the signal for apoptosis of susceptible HERV de-repressed tumor cells (“kill”), inducing a synergistic cytotoxic effect [38]. This evidence concerns the gene TLR7 and ovarian carcinoma.